Interferon-inhibiting activities in sera of patients with lung cancer.
A differential pattern of sera exhibiting interferon-inhibiting activity in cases of histologically confirmed lung cancer patients have been observed. The sera distribution was dependent on the clinical entity and the cell line specificity used measuring IFN-inhibition. Although either small cell lung cancer (SCLC) or non small cell lung cancer (NSCLC) sera exhibiting in a high percentage (80 and 75% respectively) such an activity, in any of the 3 lines tested, the ratio of sera exerting inhibition in each cell line was different. Such cell specific systems could be of prognostic/predicting value for effective therapeutic schedules of specific clinical entities.
Karmaniolas
K
K
3rd Department of Internal Medicine, NIMTS Hospital, Petraki, Athens, Greece.
Tsantakis
G
G
Havredaki
M
M
D000368:Aged; D000998:Antiviral Agents / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000097:blood / Q000378:metabolism; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000037:antagonists & inhibitors; D007372:Interferons / Q000037:antagonists & inhibitors*; D008175:Lung Neoplasms / Q000097:blood*; D008297:Male; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007372:Interferons